LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

Home・Akcijų sąrašas・Biogen Inc

Biogen Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

140.29 0.24

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

140.04

Max

141.94

Pagrindiniai rodikliai
By Trading Economics
Pajamos	394M 635M
Pardavimai	215M 2.6B
P/E Sektoriaus vid.	12.653 35.733
Pelnas, tenkantis vienai akcijai	3.02
Pelno marža	23.995
Darbuotojai	7,605
EBITDA	457M 1B

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+20.72% upside

Dividendai
By Dow Jones
Kitas uždarbis	2025-10-29

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	442M 19B
Ankstesnė atidarymo kaina	140.05
Ankstesnė uždarymo kaina	140.29

Naujienos nuotaikos

By Acuity

31%

69%

92 / 371 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bearish Evidence

118.15 / 121.17 Palaikymas ir pasipriešinimas

Biogen Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-09-06 09:30; UTC

Įsigijimai, susijungimai, perėmimai

Armani Stuck to the Classics. But His Business Needs a Refresh -- Heard on the Street -- WSJ

2025-09-06 08:20; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-09-05 20:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-09-05 20:37; UTC

Įsigijimai, susijungimai, perėmimai

Blue Water: Assets of Auction Include Nationwide Retail Distribution Network of More Than 4,000 Branded Service Stations >BLUWU

2025-09-05 20:37; UTC

Įsigijimai, susijungimai, perėmimai

Blue Water: Assets of Auction Include Lubricant and Blending Plants Supporting Specialty Fuels and Lubricants >BLUWU

2025-09-05 20:36; UTC

Įsigijimai, susijungimai, perėmimai

Blue Water: Assets of Auction Include Midstream Infrastructure, Including Pipelines and Terminals Such as the Sour Lake Crude Pipeline >BLUWU

2025-09-05 20:36; UTC

Įsigijimai, susijungimai, perėmimai

Blue Water: Assets of Auction Include Refineries at Lake Charles, La., Lemont, Ill., Corpus Christi, Texas, With Combined Refining Capacity Exceeding 800,000 Barrels per Day >BLUWU

2025-09-05 20:33; UTC

Įsigijimai, susijungimai, perėmimai

Blue Water: Proposal Would Provide $3.2B Settlement for Holders of PDVSA 2020 Bonds to Be Paid Either in Cash or in Shrs of Publicly Listed Entity That Will Own Citgo >BLUWU

2025-09-05 20:33; UTC

Įsigijimai, susijungimai, perėmimai

Blue Water: Proposal Would Provide Cash or Stk Distributions to PDV Holding Inc.'s General Creditors >BLUWU

2025-09-05 20:31; UTC

Įsigijimai, susijungimai, perėmimai

Blue Water Acquisition Corp. III: Announces Submission of $10B Bid for PDV Holding Inc., Parent of Citgo Petroleum Corp.

2025-09-05 20:20; UTC

Uždarbis

These Stocks Moved the Most Today: Broadcom, Nvidia, Lululemon, Tesla, Samsara, Kenvue, Guidewire, and More -- Barrons.com

2025-09-05 19:23; UTC

Rinkos pokalbiai

Oil Futures Extend Losses Ahead of OPEC+ Meeting -- Market Talk

2025-09-05 19:22; UTC

Uždarbis

Week's Best: Insurance Costs, Like Sea Levels, Are Rising -- Barrons.com

2025-09-05 19:17; UTC

Rinkos pokalbiai

U.S. Natural Gas Snaps Winning Streak -- Market Talk

2025-09-05 18:59; UTC

Uždarbis

These Stocks Are Moving the Most Today: Broadcom, Nvidia, Lululemon, Tesla, Samsara, Kenvue, Guidewire, and More -- Barrons.com

2025-09-05 18:35; UTC

Rinkos pokalbiai

BMO Leans Toward September Canada Rate Cut After 'Exceptionally Weak' Jobs Report -- Market Talk

2025-09-05 17:25; UTC

Rinkos pokalbiai

Bets on Hefty Fed Cut Seen as Exaggerated -- Market Talk

2025-09-05 17:20; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Rises By 2 to 414 -- Market Talk

2025-09-05 17:17; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-09-05 17:17; UTC

Rinkos pokalbiai

Bank of Canada Policy Seen Moving to Expansionary Territory -- Market Talk

2025-09-05 17:03; UTC

Rinkos pokalbiai

Bank of Canada Expected to Cut, But Inflationary Pressures Remain a Concern -- Market Talk

2025-09-05 16:39; UTC

Įsigijimai, susijungimai, perėmimai

Yorkville Acquisition: Commencing at Market Open on Sept 8, Common Stk Will Trade on Nasdaq Under New Ticker Symbol 'MCGA' >YORK

2025-09-05 16:39; UTC

Įsigijimai, susijungimai, perėmimai

Yorkville Acquisition: Will Be Renamed to Trump Media Group CRO Strategy Upon Closing of Combination Between Yorkville, Trump Media & Technology Group Corp. and Crypto.com >YORK

2025-09-05 16:39; UTC

Įsigijimai, susijungimai, perėmimai

Yorkville Acquisition Corp.: Announces Ticker Symbol Change to 'MCGA' Ahead of Trump Media Group CRO Strategy, Inc. Listing

2025-09-05 16:39; UTC

Įsigijimai, susijungimai, perėmimai

Yorkville Acquisition: Outstanding Publicly Traded Units and Warrants Will Trade on Nasdaq Under New Ticker Symbols 'MCGAU' and 'MCGAW', Respectively >YORK

2025-09-05 16:37; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Global Equities Roundup: Market Talk

2025-09-05 16:37; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Global Energy Roundup: Market Talk

2025-09-05 16:37; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Strathcona Buys Up More MEG Shares In Effort to Scuttle Cenovus Deal -- Market Talk

2025-09-05 16:20; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-09-05 16:16; UTC

Uždarbis

These Stocks Are Moving the Most Today: Broadcom, Nvidia, Lululemon, Tesla, Samsara, Guidewire, and More -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Biogen Inc Prognozė

Kainos tikslas

By TipRanks

20.72% į viršų

12 mėnesių prognozė

Vidutinis 169.81 USD 20.72%

Aukščiausias 260 USD

Žemiausias 118 USD

Remiantis 26 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Biogen Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

26 ratings

Pirkti

Laikyti

Parduoti

Remiantis 26 analitikų, pateikusių Biogen Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

118.15 / 121.17Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

92 / 371 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.